September 9th 2017
Nab-paclitaxel (Abraxane) monotherapy has efficacy in patients with pretreated advanced nonsquamous non-small cell lung cancer that is not improved by the addition of CC-486.
September 8th 2017
Taselisib added to standard letrozole (Femara) improved the objective response rate compared to letrozole with a placebo in postmenopausal women with estrogen receptor-positive and HER2-negative early breast cancer.
July 6th 2017
Ziv-aflibercept (Zaltrap) prolonged overall survival compared to placebo across subgroups of patients with metastatic colorectal cancer with wild-type and mutated RAS, KRAS, and BRAF genes.
While expected improvements in survival did not emerge with SIRT plus chemotherapy, an unanticipated benefit was observed with SIRT in patients with metastatic colorectal cancer.
July 1st 2017
The novel stemness inhibitor napabucasin in combination with different standard chemotherapy backbones demonstrated promising activity in metastatic pancreatic adenocarcinoma and metastatic colorectal cancer.
CEA-TCB showed a favorable safety profile and promising efficacy in patients with heavily-pretreated microsatellite stable metastatic colorectal cancer, with enhanced efficacy when combined with atezolizumab.
June 30th 2017
Patients with unresectable HCC continue to show statistically significant improvement in overall survival with second-line regorafenib (Stivarga) treatment.
Durable responses and improved long-term survival were demonstrated with nivolumab (Opdivo) that were not altered by the age of patients with advanced hepatocellular carcinoma across all age groups of patients participating in the CheckMate 040 trial.
June 29th 2017
The addition of pegvorhyaluronidase alfa (PEGPH20) to standard nab-paclitaxel/gemcitabine improved progression-free survival over standard therapy in patients with metastatic pancreatic ductal adenocarcinoma.
Combination therapy with AM0010, a PEGylated human interleukein (IL)-10, plus fluorouracil (5-FU), leucovorin, and oxaliplatin (FOLFOX) demonstrated encouraging clinical activity in metastatic pancreatic ductal adenocarcinoma.
June 27th 2017
The first known trial of combined ublituximab (TG-1101), ibrutinib (Imbruvica), and umbralisib (TGR-1202) showed that the combination was well tolerated and had activity across heavily pretreated patients with high-risk B-cell malignancies.
June 26th 2017
Combination ibrutinib (Imbruvica) and venetoclax (Venclexta) set the bar high and aims to achieve eradication of minimal residual disease within a year of treatment in patients with relapsed or refractory chronic lymphocytic leukemia.
June 25th 2017
The combination of obinutuzumab and CC-122 was well tolerated and demonstrated promising response rates and durable remissions in patients with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.
CTL019, an investigational chimeric antigen receptor T-cell therapy, demonstrated high response rates and a manageable safety profile in pediatric and young adult patients with relapsed and/or refractory acute lymphoblastic leukemia.
June 24th 2017
Results from the phase III Myeloma XI study showed that patients with myeloma had deeper responses after induction and after allo-stem cell transplantation with outpatient-delivered quadruplet therapy than with sequential immunomodulatory triplet combinations.
Patients with newly-diagnosed multiple myeloma who did not elect to undergo stem cell transplant but remained on single agent ixazomib maintenance fared as well as those who received SCT.
June 23rd 2017
All patients with multiple myeloma in a phase I study showed a response following treatment with an active dose of bb2121, an investigational anti–BCMA CAR T-cell construct.
Investigators reported the characterization of early clinical and serum biomarkers that may identify specific patients with ALL being treated with 19-28z chimeric antigen receptor T cells needing an early intervention to mitigate the development of severe neurotoxicity.
June 17th 2017
Combining pembrolizumab with rituximab induced a high response rate in patients with relapsed follicular lymphoma.
Copanlisib showed an objective response rate of 59.2% without inducing major colitis events or elevation of hepatic transaminases in patients with relapsed or refractory indolent B-cell lymphoma.